• Online Features  This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (6)  • Contact me when this article is cited  Related Content  • Related letters  • Related article  • Similar articles in this journal  Topic Collections  • Neurology  • Alzheimer Disease  • Cognitive Disorders  • Diagnosis  • Alert me on articles by topic  Social Bookmarking   What's this?

A. Zara Herskovits, MD, PhD; John H. Growdon, MD

Arch Neurol. 2010;67(8):918-920. doi:10.1001/archneurol.2010.151

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

The article by De Meyer et al¹ in this month's issue of the Archives presents a novel method of analyzing cerebrospinal fluid (CSF) biomarker data and determining how these data map onto the clinical diagnoses of Alzheimer disease (AD), mild cognitive impairment (MCI), and healthy control subjects. Using a 2-component mixture model, they identified a signature of low β-amyloid 1-42 (Aβ1-42) level, high total tau protein (T-tau) level, and elevated phosphorylated tau protein 181 (P-tau 181) level that was detected in more than 90% of the AD group and only 39% of the control group; the MCI group was intermediate with 73%. Overall, the diagnostic sensitivity was 90% for AD with a specificity of 64% in 3 independent data sets. Further, the AD CSF signature of low Aβ1-42 level and high P-tau 181 level correctly identified 100% of MCI cases that . . . [Full Text of this Article]

AUTHOR INFORMATION

Author Affiliations: Department of Pathology, Brigham and Women's Hospital (Dr Herskovits) and Department of Neurology, Massachusetts General Hospital (Dr Growdon), Boston, Massachusetts.

CiteULike    Connotea    Delicious    Digg    Facebook    Reddit    Technorati    Twitter     What's this?

RELATED LETTERS

Primum non nocere
David Kuhlmann
Arch Neurol. 2011;68(3):397-398.
EXTRACT | FULL TEXT  

Primum non nocere—Reply
John H. Growdon and A. Zara Herskovits
Arch Neurol. 2011;68(3):398.
EXTRACT | FULL TEXT  

RELATED ARTICLE

Diagnosis-Independent Alzheimer Disease Biomarker Signature in Cognitively Normal Elderly People
Geert De Meyer, Fred Shapiro, Hugo Vanderstichele, Eugeen Vanmechelen, Sebastiaan Engelborghs, Peter Paul De Deyn, Els Coart, Oskar Hansson, Lennart Minthon, Henrik Zetterberg, Kaj Blennow, Leslie Shaw, John Q. Trojanowski, and for the Alzheimer's Disease Neuroimaging Initiative
Arch Neurol. 2010;67(8):949-956.
ABSTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Treat Alzheimer Disease Before It Is Symptomatic
Rosenberg
Arch Neurol 2011;68:1237-1238.
FULL TEXT  

Surgery and Anesthesia: Healing the Body but Harming the Brain?
Crosby and Culley
Anesth. Analg. 2011;112:999-1001.
FULL TEXT  

Anesthesiology Must Play a Greater Role in Patients with Alzheimer's Disease
Silbert et al.
Anesth. Analg. 2011;112:1242-1245.
FULL TEXT  

Primum non nocere
Kuhlmann
Arch Neurol 2011;68:397-398.
FULL TEXT  

Dementia: Five New Things
Filley and Anderson
Neurology 2011;76:S26-S30.
FULL TEXT